Human papillomavirus type 18 E7 protein (HPV-18 E7) (HPV-18 E7)

The Human papillomavirus type 18 (HPV-18) E7 protein is a small, zinc-binding viral oncoprotein that plays a critical role in the development and maintenance of HPV-induced malignancies, particularly cervical cancer (UniProt P06788). Its primary mechanism of oncogenesis involves the high-affinity binding and subsequent ubiquitin-mediated degradation of the retinoblastoma tumor suppressor protein (pRb) (PubMed: 10482258). This degradation releases E2F transcription factors, which constitutively activate the expression of genes required for S-phase entry, leading to uncontrolled cell proliferation (StatPearls: HPV). Additionally, HPV-18 E7 interacts with other cellular targets, such as p107 and p130, and interferes with interferon signaling to evade the host immune response (PubMed: 21734202). Because E7 expression is required for the survival of HPV-transformed cells and is not found in healthy human cells, it is a major target for therapeutic vaccines and immunotherapies (PubMed: 30206244). Current clinical candidates like VGX-3100 and INO-3112 are designed to elicit a robust CD8+ T-cell response against E7-expressing cells to treat precancerous lesions and established tumors (ClinicalTrials.gov: NCT03721978). The protein's structural stability and its role in disrupting the host's DNA damage response further contribute to its potency as a driver of carcinogenesis (PubMed: 16439325). Targeting E7 remains a cornerstone of precision oncology for HPV-positive cancers, with ongoing research into small molecule inhibitors and CRISPR-based gene disruption.

Other names

E7 proteinHPV18 E7Early protein E7Protein E7Human papillomavirus type 18 E7

The primary mechanism of action for therapeutic agents targeting this protein is the induction of a cellular immune response, specifically CD8+ cytotoxic T-lymphocytes, which recognize E7-derived peptides presented on MHC class I molecules and eliminate the infected or transformed cells (PubMed: 30206244). At the molecular level, the E7 protein itself acts by binding to the pRb pocket, displacing E2F, and recruiting the Cullin 2 ubiquitin ligase to degrade pRb (PubMed: 16439325).